Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 28, 2025Nature CommunicationsOpen Access

Silencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPengbo SunFHFangping HanXLXinyan Li

Discussion

Loading...

Member takes

Implication

Findings reveal that targeting PCSK9 boosts immunostimulatory effects in cancer immunotherapy, indicating enhanced safety and efficacy measures.

Key Points

  • PCSK9 deficiency significantly enhances immunostimulatory effects of STING agonists, boosting tumor-targeted therapy.
  • Key evidence shows effective cancer immunotherapy strategy combining STING activation modulation with PCSK9 targeting.
  • Research utilizes a unique formulation of a low-dose STING agonist with PCSK9-targeting siRNA for liver toxicity minimization.
  • These promising results highlight the therapeutic approach for enhancing safety in STING-based immunotherapies.

Cite This Study

Sun et al. (2025) studied this question.

synapsesocial.com/papers/6928f113a65b730b9ea7a041https://doi.org/10.1038/s41467-025-66630-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Silencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy2025 · 7 citations
  2. 2The cGAS–STING pathway in cancer immunotherapy: prognostic value and therapeutic potential2026 · 4 citations
  3. 3Therapeutic targeting of the cGAS-STING pathway in human disease2026 · 2 citations
  4. 4Abstract 6598: Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors2024
  5. 5Targeting VCP enhances colorectal cancer therapy through STING stabilization2025